Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

PURPOSE: Checkpoint therapy is now the cornerstone of treatment for patients with renal cell carcinoma (RCC) with advanced disease, but biomarkers are lacking to predict which patients will benefit. This study proposes potential immunological biomarkers that could developed for predicting therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlisle, Jennifer Wilkinson, Jansen, Caroline S, Cardenas, Maria Andrea, Sobierajska, Ewelina, Reyes, Adriana Moon, Greenwald, Rachel, Del Balzo, Luke, Prokhnevska, Nataliya, Kucuk, Omer, Carthon, Bradley C, Mullane, Patrick Connor, Osunkoya, Adeboye, Baumgarten, Deborah, Hosseinzadeh, Fares, Wilkinson, Scott, Lake, Ross, Sowalsky, Adam G, Liu, Yuan, Master, Viraj A, Bilen, Mehmet A, Kissick, Haydn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310235/
https://www.ncbi.nlm.nih.gov/pubmed/35863822
http://dx.doi.org/10.1136/jitc-2022-004803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310235/
https://www.ncbi.nlm.nih.gov/pubmed/35863822
http://dx.doi.org/10.1136/jitc-2022-004803

Ejemplares similares